Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs.

Protein science : a publication of the Protein Society - 1 Oct 2025

Halder Ritaban, Warshel Arieh

Abstract excerpt

Hypertrophic cardiomyopathy (HCM) is an inherited form of heart disease, caused by specific mutations, many of which are encoded by the β-cardiac myosin (MYH7) protein. This work provides molecular insight into the effect of an HCM-causing mutation, R190T of β-cardiac myosin. The Arginine190 (R190) resides near the active site of the cardiac myosin and its alteration by a threonine (T190) residue leads to cardiac...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac Myosins
Share to Cardiomyopathy, Hypertrophic
Share to MYH7 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Dynamics Simulation

Share to Mutation

Share to Myosin Heavy Chains

Source

Open in PubMed Open full text

Identifiers

PMID: 40944412
DOI: 10.1002/pro.70289
PMCID: PMC12432434

Genes

MYH7

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs.PMID 40944412Read ↗

Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism.Semantic proximity Read ↗

Human cardiac β-myosin powerstroke energetics: Thin filament, Pi displacement, and mutation effects.Semantic proximity Read ↗

Dilated cardiomyopathy mutation in beta-cardiac myosin enhances actin activation of the power stroke and phosphate releaseSemantic proximity Read ↗

Hypertrophic cardiomyopathy ß-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super-relaxed stateSemantic proximity Read ↗

A myosin hypertrophic cardiomyopathy mutation disrupts the super-relaxed state and boosts contractility by enhanced actin attachmentSemantic proximity Read ↗

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionSemantic proximity Read ↗

The hypertrophic cardiomyopathy mutation G768R makes cardiac myosin a high duty ratio motorSemantic proximity Read ↗

Integrating comparative modeling and accelerated simulations reveals conformational and energetic basis of actomyosin force generationSemantic proximity Read ↗

Human hypertrophic cardiomyopathy mutation R712L suppresses the working stroke of cardiac myosin and can be rescued by omecamtiv mecarbilSemantic proximity Read ↗

The G256E HCM mutation prolongs relaxation via altered nucleotide handlingSemantic proximity Read ↗

Molecular Effects of cTnC DCM Mutations on Calcium Sensitivity and Myofilament Activation-An Integrated Multiscale Modeling Study.Semantic proximity Read ↗

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.